Ceramide NanoLiposome in Patients With Advanced Solid Tumors

Inclusion Criteria: * Signed informed consent/authorization is obtained prior to conducting any study-specific screening procedures. * 18 years of age or order * Histologic or cytologic diagnosis of cancer * Patients without a curative therapy or whose tumor does not have standard chemotherapy * At least 4 weeks after the last dose of chemotherapy or radiation therapy; 6 weeks for mitoxantrone or mitomycin therapy * Eastern Cooperative Oncology Group (ECOG) performance status must be ≤2 (Appendix A). * Adequate hepatic, renal, and bone marrow function: * Absolute neutrophil count ≥ 1,000/microliter (uL) * Platelets ≥ 100,000/uL * Total bilirubin ≤2.0 * AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN * Creatinine ≤1.2 mg/dL or clearance ≥50ml/min (Cockcroft-Gault) * All participants (male and female) with reproductive potential must practice an effective method of contraception while on this study in order to minimize risks to fetuses. * Radiographic evidence of measurable disease tumor lesion (≥ 1cm in greatest dimension) or nodal disease (\>1.5cm in greatest dimension) * Men and women of all ethnic groups are eligible for this trial. * Females at reproductive age must have a negative urine pregnancy test prior to entry to this study * Life expectancy is greater than 12 weeks. * Patients with controlled CNS disease and off steroids are eligible. Exclusion Criteria: * Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol. * Since the teratogenic potential of this combination is currently unknown, females who are pregnant or lactating are excluded. Males and females should perform abstinence or use barrier to prevent pregnancy. * History of any other malignancies in the last 2 years except in-situ cancer, non-muscle invasive bladder cancer, basal or squamous cell skin cancer are eligible * Patients known to be HIV(+), Hep BsAg(+), or Hep C(+) are excluded as the effect of the agent on immune system has not been assessed * Patients with history of hypersensitivity to liposomal products * Patients with primary CNS malignancies or leptomeningeal disease are excluded